Benchmark Holdings’ sale of its Genetics business to Novo Holdings announced in November 2024 is guided to close in calendar Q1 2025. The initial consideration of GBP230m (plus GBP30m in potential earnout) is set to be used to pay down debt and excess capital returned to shareholders. We have adjusted our estimates after the Q1 results, as Benchmark Holdings will retain more short-term corporate costs than previously expected. We reiterate our BUY but have cut our target price to NOK6.3 (7.2).
Q4 revenue of GBP36.8m and adj. EBITDA of GBP6.9m were both 13% below our estimates, while the adj. EBITDA margin of 18.8% was in line. The company said it would refocus on the remaining businesses following the pending sale of Genetics and aims to pay down debt and return excess cash to shareholders. We estimate an extraordinary dividend of GBP160m in Q2 2025. We calculate the stub is trading at a 2025–2026e EV/EBITDA of 4.7–5.9x. We reiterate our BUY and have raised our target price to NOK7.2 ...
Today Benchmark Holdings announced the sale of its genetics business to Novo Holding for a total potential consideration of GBP260m, equivalent to 17.9x EV/EBITDA – at 16% above our SOTP, we find this attractive. Following the transaction, the company will repay loans, focus on the remaining business and terminate its strategic review.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.